AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 130 filers reported holding AIMMUNE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 3.37 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $0 | – | 0 | – | 0.00% | – |
Q1 2021 | $0 | – | 0 | – | 0.00% | – |
Q4 2020 | $0 | -100.0% | 0 | -100.0% | 0.00% | – |
Q3 2020 | $1,000 | -97.7% | 15 | -99.4% | 0.00% | -100.0% |
Q2 2020 | $44,000 | +2.3% | 2,660 | -14.9% | 0.00% | -25.0% |
Q1 2020 | $43,000 | -47.6% | 3,126 | +23.5% | 0.00% | -33.3% |
Q4 2019 | $82,000 | +86.4% | 2,532 | +23.9% | 0.01% | +100.0% |
Q3 2019 | $44,000 | +1366.7% | 2,044 | +1741.4% | 0.00% | – |
Q4 2018 | $3,000 | 0.0% | 111 | 0.0% | 0.00% | – |
Q3 2018 | $3,000 | -92.7% | 111 | -92.6% | 0.00% | -100.0% |
Q2 2018 | $41,000 | -39.7% | 1,508 | -16.0% | 0.00% | -33.3% |
Q1 2018 | $68,000 | 0.0% | 1,795 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $68,000 | – | 1,795 | +10458.8% | 0.00% | – |
Q3 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
Q2 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
Q1 2017 | $0 | – | 17 | 0.0% | 0.00% | – |
Q4 2016 | $0 | – | 17 | 0.0% | 0.00% | – |
Q3 2016 | $0 | – | 17 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management II, LLC | 3,300,797 | $90,046,000 | 33.32% |
Aisling Capital LLC | 1,990,000 | $54,287,000 | 11.73% |
Foresite Capital Management III, LLC | 801,240 | $21,858,000 | 4.82% |
PACIFIC VIEW ASSET MANAGEMENT, LLC | 189,857 | $5,181,000 | 4.12% |
AlpInvest Partners B.V. | 38,943 | $1,062,000 | 2.27% |
Eventide Asset Management | 1,739,000 | $47,440,000 | 1.74% |
Palo Alto Investors LP | 1,381,759 | $37,694,000 | 1.52% |
Sofinnova Investments, Inc. | 222,295 | $6,064,000 | 0.54% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 553,000 | $15,086,000 | 0.54% |
EMERALD ADVISERS, LLC | 486,666 | $13,276,000 | 0.49% |